Image

TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics

TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics

Recruiting
50-77 years
All
Phase N/A

Powered by AI

Overview

Aim 1: Culturally adapt the TELESCOPE intervention for Hispanics. Using iterative qualitative feedback from a study-specific Community Advisory Board, focus groups, and interviews with community members, the investigators will culturally adapt the TELESCOPE intervention for Hispanics at high risk for lung cancer.

Aim 2: Assess the feasibility, acceptability, and implementation potential of the culturally adapted TELESCOPE intervention delivered by bilingual patient navigators for Hispanics. Hypothesis 1: The investigators expect a recruitment rate of ≥60%, ≥90% of Hispanic participants will complete the 1-week follow-up assessments, ≥80% of the key intervention components will be delivered with 80% fidelity by the patient navigators, and ≥90% of participants and clinicians will agree or completely agree that the intervention was feasible and acceptable.

Aim 3: Explore the impact of a culturally adapted TELESCOPE intervention delivered by bilingual patient navigators vs enhanced usual care (EUC) on the initial uptake of low-dose computed tomography (LDCT) and quality of the shared decision-making (SDM) process. Hypothesis 2: The investigators expect that an adapted TELESCOPE intervention will result in higher uptake of LDCT and higher SDM quality for lung cancer screening (LCS) compared to EUC.

Description

This pilot feasibility trial aims to culturally adapt an existing TELESCOPE (R01HL158850) intervention to create a culturally appropriate SDM and navigation intervention for Hispanics in primary care settings. The investigators will assess its feasibility and acceptability (primary outcomes), and explore its impact on the uptake of LDCT (secondary outcome) compared to enhanced usual care (training clinicians to discuss LCS) for LCS in Hispanics.

Eligibility

Inclusion Criteria:

Aim 1 (Cultural Adaptation):

To be eligible, patients must:

  1. Identify as Hispanic and/or Latino(a)
  2. Able to read and speak in English or Spanish
  3. Be 50 to 77 years of age
  4. Be a current or former smoker
  5. Have at least a 20-pack-year smoking history

Aims 2-3 (Pilot Randomized Controlled Trial)

To be eligible, patients must:

  • Identify as Hispanic or Latino(a)
  • Able to speak and read in English or Spanish
  • Be 50 to 77 years of age
  • Be a current or former smoker having quit within the past 15 years
  • Have at least a 20 pack-year smoking history
  • Be scheduled for a non-acute care visit at one of the study sites.
  • Not coughing up blood in the last two weeks

Interviews

Providers completing the semi-structured interviews will be:

  • A practicing primary care clinician or a clinic director (n=20), nursing director, or clinic practice administrator at one of the participating sites, or a TELESCOPE study patient navigator and nurse navigator
  • Age 18 or older
  • Fluent in English

Online surveys

Providers completing online PRISM construct surveys will be:

  • A practicing primary care provider at one of the participating sites or a TELESCOPE study navigator
  • Age 18 or older
  • Fluent in English

Exclusion Criteria:

For the cluster randomized trial, excluded will be patients who:

  • Do not speak English
  • Are not Hispanic or Latino(a)
  • Have a history of lung cancer
  • Had a CT scan in the past 12 months
  • Has been coughing up blood in the last two weeks
  • Have health conditions that make them poor candidates for curative treatment as determined by the primary care provider,
  • Are unable to provide informed consent Interviews

Providers/administrators will be excluded if they:

  • Are unable to provide informed consent Online surveys
  • Are unable to provide informed consent
  • Women who are pregnant.

Study details
    Lung Neoplasms

NCT07165691

Rutgers, The State University of New Jersey

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.